56468-23-6

Usage

Uses

Used in Pharmaceutical Industry:
8-Chloroimidazo[1,5-a]pyrazine is utilized as an intermediate in the synthesis of various drugs and pharmaceuticals. Its unique structure and functional groups make it a key component in the creation of new medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 8-chloroiMidazo[1,5-a]pyrazine serves as a building block for the preparation of novel compounds. Its versatility in forming different chemical entities allows for the exploration of new chemical spaces and the development of innovative materials and substances.
Used in Medicinal Chemistry Research:
8-Chloroimidazo[1,5-a]pyrazine is considered a useful tool in medicinal chemistry research. Its properties and reactivity contribute to the understanding of molecular interactions and the design of new therapeutic agents, thereby advancing the discovery and optimization of potential drug candidates.

Upstream product

• 940307-81-3 N-((3-chloropyrazin-2-yl)methyl)carboxamide 
• 771581-15-8 (3-chloro-pyrazin-2-yl)-methylamine 

Downstream Products

• 1195989-58-2 C₁₆H₁₆ClN₃O 
• 1195989-57-1 C₁₄H₁₂ClN₃O₂ 
• 1195989-56-0 C₇H₄ClN₃O 
• 1195989-64-0 C₈H₈ClN₃ 
• 56468-24-7 8-chloro-3-methylimidazo[1,5-a]pyrazine 
• 1502776-60-4 3-bromo-8-chloroimidazo[1,5-a]pyrazine 

Relevant academic research and scientific papers

Novel Bruton's tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a reversible novel Bruton's tyrosine kinase inhibitor which comprises a compound of a formula (I) as shown in the specification, and a stereisomer, a aquo-complex, a solvent compound, a pharmaceutically acceptable salt, an eutectic crystal or a predrug of the compound. The invention further relates to a preparation method of the compound and a method and the application ofthe novel compound in inhibiting BTK (Bruton's Tyrosine Kinase) kinase activity and mutant BTK kinase activity.

BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

BICYCLIC PROTEIN KINASE INHIBITORS

Compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit prote